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miRNA-36 inhibits KSHV, EBV, 
HSV-2 infection of cells via stifling 
expression of interferon induced 
transmembrane protein 1 (IFITM1)
Hosni A. M. Hussein & Shaw M. Akula
Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically associated with all forms of Kaposi’s 
sarcoma worldwide. Little is currently known about the role of microRNAs (miRNAs) in KSHV entry. 
We recently demonstrated that KSHV induces a plethora of host cell miRNAs during the early stages of 
infection. In this study, we show the ability of host cell novel miR-36 to specifically inhibit KSHV-induced 
expression of interferon induced transmembrane protein 1 (IFITM1) to limit virus infection of cells. 
Transfecting cells with miR-36 mimic specifically lowered IFITM1 expression and thereby significantly 
dampening KSHV infection. In contrast, inhibition of miR-36 using miR-36 inhibitor had the direct 
opposite effect on KSHV infection of cells, allowing enhanced viral infection of cells. The effect of miR-
36 on KSHV infection of cells was at a post-binding stage of virus entry. The highlight of this work was 
in deciphering a common theme in the ability of miR-36 to regulate infection of closely related DNA 
viruses: KSHV, Epstein-Barr virus (EBV), and herpes simplexvirus-2 (HSV-2). Taken together, we report 
for the first time the ability of host cell miRNA to regulate internalization of KSHV, EBV, and HSV-2 in 
hematopoietic and endothelial cells.
Kaposi’s sarcoma-associated herpesvirus (KSHV) causes Kaposi’s sarcoma (KS)1. To a lesser extent, KSHV is 
etiologically associated with rare neoplastic disorders like primary effusion lymphoma (PEL), and multicentric 
Castleman disease (MCD)2. KS is a malignant vascular tumor characterized by lesions occurring mainly on the 
skin, but can also affect the mucosa and visceral organs3. Hallmarks of KS are angiogenesis, cell proliferation, 
and inflammation4. KSHV is among the list of viral pathogens estimated to cause 12–25% of human cancers 
worldwide5.
KSHV has a biphasic life cycle comprised of latent and lytic phases of replication that are distinguished 
based on divergent gene expression profiles6. The dynamics between latent and lytic phases of replication allows 
the virus to persist for the duration of the host’s lifetime7. Notably, KSHV establishes latency in the majority 
of infected cells8; at any given instance, only a subpopulation (<3%) of infected cells display evidence of lytic 
gene expression9. MicroRNAs (miRNAs) are one of the main classes of non-coding RNAs10. These are small 
non-coding RNAs that regulate expression of genes in cells11. The human genome encodes thousands of miR-
NAs12. Of late, miRNAs have emerged as a pivotal component of host cell responses to a pathogen including 
viruses, bacteria, and fungi13.
KSHV, human immunodeficiency virus 1 (HIV-1), Epstein-Barr virus (EBV), and herpes simplex virus type 1 
(HSV-1) are few examples of the limited number of viruses that encode their own miRNAs14,15. KSHV encodes 12 
pre-miRNAs which are processed to yield 25 mature miRNAs16. The roles of these KSHV-encoded miRNAs is to 
establish and/or maintain KSHV latency, enhance angiogenesis, spread infected cells, and interfere with the host 
immune system; all of which are crucial to oncogenesis17. Extensive work has been conducted on KSHV encoded 
miRNAs and the manner by which KSHV replication alters cellular miRNAs18,19. However, there is limited work 
along the lines of understanding the effects of cellular miRNAs in response to early stages of KSHV infection of 
cells; specifically internalization of the virus. Recently, we employed deep sequencing for the first time, to analyze 
the miRNA expression profile in KSHV-infected BJAB cells during early stages of infection20. In this study, we 
attempted to decipher how the cellular miRNA-36 (miR-36) alters KSHV infection in physiologically relevant 
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cells: human B, and endothelial cells. We focused on the expression and effects of cellular miR-36 in response to 
KSHV infection because it was consistently elevated at 15 and 30 min post infection (PI). Our data showed that 
the over-expression of cellular miR-36 inhibits KSHV infection of cells by dampening expression of interferon 
induced transmembrane protein 1 (IFITM1). Interestingly, the effect of IFITM1 on the closely related virus, 
Epstein-Barr virus (EBV) and a distant relative, herpes simplex virus-2 (HSV-2) followed the same pattern as in 
KSHV. These results reveal a layer of common theme in the regulation of host cell genes by miRNAs in the inter-
nalization of KSHV and related viruses.
Results
KSHV infection of cells induces host cell miR-36 during early stages of KSHV infection. In a 
recently concluded study, we described a significant increase in the expression of host cell encoded miR-36 as early 
as 15 min PI of cells20. In the present study, we monitored expression of this miR-36 at early time points during 
KSHV infection of human B and endothelial cells. We employed human B (BJAB) and endothelial (HMVEC-d) 
cells as they are physiologically relevant cells to KSHV biology. Expression of miR-36 gradually increased from 
5 min PI and peaked at 30 min PI in KSHV infected BJAB (Fig. 1A) and HMVEC-d cells (Fig. 1B). Uninfected 
BJAB and HMVEC-d cells did not express miR-36 (Fig. 1A,B). Expression of known miRNAs, hsa-let-7c and hsa-
miR-3130-5p, were not significantly altered when compared to miR-36 during early stages of KSHV infection of 
cells (Fig. 1A,B). Treatment of cells with 10 units/ml of heparinase I/III for 2 h at 37 °C prior to KSHV infection of 
cells resulted in a significant drop in the expression of miR-36 in BJAB (Fig. 1C) and HMVEC-d cells (Fig. 1D). 
Also, infection of both BJAB and HMVEC-d cells with UV.KSHV could induce the expression of miR-36 to com-
parable levels as the wild-type KSHV (Fig. 1C,D). These results demonstrate KSHV to induce host cell miR-36 
very early upon infection. Key features of the novel miR-36 including the secondary structure are provided in 
Table 1 and supplemental Fig. 1, respectively.
miR-36 inhibits KSHV infection in BJAB and HMVEC-d cells. To evaluate the biological effects of 
miR-36 in target cells, we analyzed the effects of miR-36 mimic and inhibitor on KSHV infection. The range 
of doses tested in this study is comparable to those reported in the earlier studies21–25. The doses of the mimic 
Figure 1. KSHV induces the expression of miR-36 at an early stage of infection. Expression of miR-36, has-
let-7c, and has-miR-3130-5p were detected by qRT-PCR at different time points post-infection in cells infected 
with 10 MOI of KSHV compared to uninfected cells. The qRT-PCR data was plotted for fold changes in the 
expression of miR-36, has-let-7c and has-miR-3130-5p in (A) BJAB cells, and (B) HMVEC-d. BJAB (C) and 
HMVEC-d (D) cells were either untreated or treated with heparinase I/III prior to performing the infection 
assay followed by monitoring the expression of miR-36. UV.KSHV was used in this study as a control to 
understand the importance of an intact virus envelope and associated proteins in inducing miR-36. The relative 
expression of miRNAs was measured in terms of cycle threshold value (Ct) and normalized to snRNA RNU6B. 
The x-axis indicates the time points post KSHV infection in minutes and y-axis indicates fold change in the 
expression of miR-36. Bars (panels A,B,C,D) represent average ± s.d. of five individual experiments. (A,B) 
Student t test was performed to compare expression of miR-36 in uninfected cells versus 5, 10, 15, and 30 min 
PI. In panels ‘C and D’, Student t test was performed to study the effect of HS and compare infection of cells with 
KSHV versus UV.KSHV on miR-36 expression at 5, 10, 15, and 30 min PI. Two-tailed P value of 0.05 or less was 
considered statistically significant. *p < 0.05; **p,0.01; ***p < 0.001; NS-not significant.
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and inhibitor used in the study did not significantly induce cell death in BJAB and HMVEC-d cells (Fig. 2A,B). 
Transfection of BJAB (Fig. 2C) and HMVEC-d (Fig. 2D) cells with miR-36 mimic significantly reduced KSHV 
infection of cells as monitored by the expression of ORF50 gene as early as 30 min PI. KSHV entry is a quick 
process and the IE gene, ORF50, is expressed immediately upon infection26. KSHV infection was not significantly 
altered in BJAB (Fig. 2C) and HMVEC-d (Fig. 2D) cells that were either transfected with scrambled miRNA 
control (miR-NC) or mock transfected. Interestingly, the effect of miR-36 mimic on KSHV infection of BJAB and 
HMVEC-d cells could be significantly reversed by co-transfecting cells with 10 nM of miR-36 inhibitor (Fig. 2E). 
Co-transfection of cells with miR-NS did not alter the effects of miR-36 mimic (Fig. 2E). To ascertain that the 
effect of miR-36 mimic was at a post-binding stage of infection, we performed a binding assay. The binding assay 
performed on BJAB and HMVEC-d cells demonstrated that miR-36 mimic and the miR-36 inhibitor did not 
block KSHV from binding the target cells (Fig. 2F). Incubating KSHV with heparin but not CSA significantly 
blocked KSHV from binding cells (Fig. 2F). Our results clearly implicate miR-36 to inhibit KSHV infection of 
cells. To extend our understanding of the role of miR-36 on other related viruses, we tested the effect of miR-36 
mimic and the miR-36 inhibitor on EBV and HSV-2 infection of BJAB cells. Interestingly, miR-36 mimic could 
significantly block EBV and HSV-2 infection of BJAB cells and this inhibition could be specifically reversed by 
the miR-inhibitor (Fig. 3).
miR-36 targets IFITM1. By using the DIANA and MiRmap tool algorithms, we identified a putative miR-36 
binding site located in the 3′-UTR of IFITM1 mRNA (Supplemental Fig. 2). To confirm the ability of miR-36 to 
specifically inhibit IFITM1 expression, we monitored the expression of IFITM1 in target cells that were untrans-
fected, transfected with miR-36 mimic, or miR-NC prior to infection. Transfection of BJAB and HMVEC-d cells 
with miR-36 mimic significantly lowered the expression of IFITM1 at 15 min PI compared to untransfected cells 
and cells transfected with miR-NC (Fig. 4A). Transfection of cells with miR-36 mimic could specifically inhibit 
IFITM1 expression from 5 min till 48 h PI (data not shown). These results authenticate the fact that IFITM1 
expression may well be regulated by miR-36.
In order to determine the bona fide target of miR-36, a luciferase reporter assay was performed. In this assay, 
two quantifiable genes encoding luciferase proteins were put on a vector. The IFITM1 3′ UTR with the target 
region was placed downstream GLuc to regulate its translation, and SEAP was placed under no regulation for 
normalization. 293 cells were co-transfected with the IFITM1 3′ UTR vector plasmid and miR-36 mimic. miR-
36 mimic significantly decreased the relative luciferase activity compared to the cells that were transfected with 
miR-NC (Fig. 4B). In contrast, transfection of cells with miR-inihibitor reversed the ability of miR-36 mimic from 
lowering the luciferase activity (Fig. 4B). There was an inverse correlation observed in the expression of miR-36 
and IFITM1 during the course of KSHV infection of BJAB (Fig. 4C) and HMVEC-d (Fig. 4D) cells. These results 
suggest that miR-36 directly targets IFITM1 and thereby downregulates its expression.
IFITM1 expression enhances KSHV, EBV, and HSV-2 infection of cells. IFITM1 protein expression 
was significantly elevated with KSHV infection of BJAB and HMVEC-d cells (Fig. 5A). The expression of IFITM1 
increased in KSHV infected cells as early as 5 min PI which was elevated by 15 min and 10 min PI in BJAB and 
HMVEC-d cells, respectively, but declined sharply by 30 min PI (Fig. 5A). To confirm a role for IFITM1 in KSHV 
infection of target cells, we transiently transfected BJAB and HMVEC-d cells with pQCXIP/IFITM1 and the 
expression of IFITM1 was confirmed by flow cytometry (Fig. 5B). KSHV infection of the above IFITM1 express-
ing BJAB and HMVEC-d cells was a measure of the expression of ORF50 at 30 min PI. The idea was to strictly 
understand the effects of IFITM1 expression on early stages of KSHV infection. BJAB (Fig. 5C) and HMVEC-d 
(Fig. 5D) cells expressing IFITM1 supported a significantly enhanced KSHV infection compared to those cells 
that were left untransfected, mock transfected, or transfected with the empty vector. Surprisingly, IFITM1 
expression also enhanced HSV-2 and EBV infection of BJAB and HMVEC-d cells (Fig. 5C,D). Interestingly, 
co-transfection of the above cells with miR-36 mimic could significantly drop KSHV infection of cells compared 
to miR-NC (Fig. 5C,D).
To further confirm the role of IFITM1 in KSHV infection of cells, we first transfected cells with siRNA specific 
for IFITM1. Northern blotting was performed at 0, 12, 24, and 48 hours after transfection as per the standard pro-
tocols to monitor IFITM1 mRNA expression (Fig. 6A). The levels of IFITM1 mRNA was significantly suppressed 












Table 1. Characteristics of miR-36.
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inhibition of 82% ± 7%, 74% ± 9%, and 45% ± 6% was observed in BJAB cells at 12, 24, and 48 hours, respectively, 
after siRNA transfection (Fig. 6A). A IFITM1 mRNA inhibition of 78% ± 9%, 65% ± 7%, and 34% ± 7% was 
observed in HMVEC-d cells at 12, 24, and 48 hours, respectively, after siRNA transfection. IFITM1 expression 
levels were not significantly altered by the (NS)siRNA controls in both the cells tested, demonstrating the specific-
ity of the siRNA used (Fig. 6A). IFITM1 expression in target cells transfected with siRNA specific to IFITM1 was 
significantly lowered at 15 min post KSHV infection (Fig. 6B). In contrast, KSHV induced IFITM1 expression in 
untransfected or cells transfected with (NS)siRNA were not altered (Fig. 6B). On the same lines, KSHV infection 
in cells silenced for the expression of IFITM1 was significantly lower compared to cells that were untransfected 
or transfected with (NS)siRNA (Fig. 6C). Silencing the expression of IFITM1 also decreased EBV and HSV-2 
infection of the above cells (Fig. 6C). The above viral infections were monitored by performing qRT-PCR. Taken 
together, the results clearly implicate a role for IFITM1 in enhancing KSHV, EBV, and HSV-2 infection of cells.
Discussion
Since miRNAs discovery over 20 years ago, miRNAs have been established as key players in the molecular mech-
anisms of mammalian biology including the maintenance of normal homeostasis and the regulation of disease 
pathogenesis. Host miRNAs also play a crucial role in mounting an immune response against microbial infec-
tions including those caused by viruses27. Several viruses belonging to herpesvirus, polyomavirus, hepadnavirus, 
Figure 2. miR-36 overexpression inhibits KSHV infection of cells. To determine the cytotoxic effect of miR-36 
mimic and inhibitor, cells were transfected with different concentrations of miR-36 mimic and inhibitor. At 
24 h post transfection, lactate dehydrogenase release as an indicator of percentage of cell death was monitored 
for miR-36 mimic (miR-mimic) (A) and miR-inhibitor (B). Known inducers of cell death, 1 mg/ml G418 
in the case of BJAB cells and 2.5 µg/ml Cytochalasin D for HMVEC-d, were used as positive controls in this 
study. (C,D) Transfection of cells with miR-36 mimic specifically inhibit KSHV infection of cells. (C) BJAB 
and (D) HMVEC-d cells were either untransfected, mock transfected, or transiently transfected with different 
concentrations of miR-36 mimic or control mimic (miR-NC) before infection with 10 MOI of KSHV. Data 
was plotted to represent the percentage of KSHV infection as determined by monitoring the change in KSHV-
ORF50 RNA copy numbers that were detected in transfected cells compared to that detected in untransfected 
cells (1905 KSHV-ORF50 RNA copies). Expression of ORF50 was used as a scale to measure KSHV infection 
of cells. As reported earlier29, the lowest limit of detection in the standard samples was 6–60 copies for the 
ORF50 gene. (E) Transfection of cells with miR-36 inhibitor opposes the effects of miR-36 mimic on KSHV 
infection of cells. BJAB and HMVEC-d were either untransfected, mock transfected, transiently transfected 
with miR-36 mimic, co-transfected with miR-36 mimic and miR-36 inhibitor (miR-mimic + mir-inhib), or co-
transfected with miR-36 mimic and nonspecific inhibitor (miR-mimic + mir-NS) before infection with KSHV. 
Data was plotted to represent the percentage of KSHV infection in transfected cells compared to untransfected 
cells. The x-axis indicates the transfection and y-axis indicates the percentage of KSHV infection. (F) miR-36 
mimic inhibition of KSHV infection of cells is at a post-attachment stage of virus entry. KSHV binding to BJAB 
and HMVEC-d that were untransfected, mock transfected, transiently transfected with miR-36 mimic, co-
transfected with miR-36 mimic and miR-36 inhibitor(miR-mimic + mir-inhib), co-transfected with miR-36 
mimic and nonspecific inhibitor (miR-mimic + mir-NS), or untransfected and treated with Heparin or CSA. 
Data was plotted to represent the percentage of KSHV binding to target cells treated differently compared to 
the untransfected cells. Bars (panels A–F) represent average ± s.d. of five individual experiments. Student t test 
was performed to compare groups. Two-tailed P value of 0.05 or less was considered statistically significant. 
*p < 0.05; **p,0.01; ***p < 0.001; NS-not significant.
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adenovirus, and retrovirus encode miRNAs14,15. Virus-encoded miRNAs (vmiRNA) identified in virus-infected 
cells significantly influence viral replication and disease progression by modulating viral as well as host cellular 
mRNA. Many of the cellular miRNAs affect viral replication either directly by binding to the viral genome or indi-
rectly by targeting host factors related to replication28. There are several published works that describe virus and 
cellular encoded miRNAs in KSHV pathogenesis10,18. However, to date, there is no report on the role of cellular 
miRNAs during early stages of KSHV infection.
Recent studies from our laboratory using a combination of deep sequencing and qRT-PCR identified cel-
lular miR-36 to activate as early as 15 min PI20. In the current studies, we employed physiologically relevant 
human B cells (BJAB) and endothelial cells (HMVEC-d) to make the study more meaningful to KSHV biology. 
Accordingly, using specific primers we analyzed the expression profile of cellular miR-36 during the first 30 min 
of KSHV infection of cells. A successful viral entry was a measure of KSHV to enter cells and express immedi-
ate early gene, ORF50. The expression of ORF50 was monitored by qRT-PCR26,29. KSHV infection of BJAB and 
HMVEC-d cells rapidly triggered the expression of miR-36 as early as 5 min PI that peaked at 30 min PI (Fig. 1). 
Expression of miR-36 in KSHV infected BJAB is higher than those in HMVEC cells. This could be attributed to 
the inherited variations observed between different cells in the manner by which they respond to virus infec-
tion30. Moreover, the expression level of miRNAs has been shown to vary among tissues, cell types, and even 
between cells of the same lineage31,32.
Cellular miR-36 is triggered by UV.KSHV infection of cells while treating target cells with heparinase I/III 
prior to infecting cells with the wild-type KSHV failed to induce expression of miR-36. Treatment of cells with 
heparinase I/III cleave heparan sulfate (HS) at different sites and liberate them from the cell surface33. KSHV 
binds to a target cell via interacting with HS expressed on the cell surface34. Taken together, our results indicate 
the following: (i) it is the interactions between the virus envelope proteins and the host cells that trigger miR-36 
response; and (ii) binding of KSHV to cells is critical to miR-36 expression in cells. miR-36 mimic specifically 
inhibited KSHV infection of BJAB and HMVEC-d cells (Fig. 2C,D). Transfection of cells with miR-36 inhibitor 
reversed the effects of miR-36 mimic on KSHV infection of cells (Fig. 2E). The effects of miR-36 mimic and 
inhibitor was specific as the scramble negative control (miR-NC) and non-specific inhibitor (miR-NS) did not 
significantly alter KSHV infection of cells (Fig. 2C,D,E). It was concluded that the effects of miR-36 mimic and 
inhibitor on KSHV infection was at a post attachment stage of internalization as they did not adversely affect virus 
binding to cells (Fig. 2F).
In this study, we originally wanted to use two relevant viruses as negative controls to better understand the 
specificity of miR-36 on KSHV infection of cells. EBV and HSV-2 were selected as controls: EBV, like KSHV, 
belongs to γ-herpesvirinae while HSV-2 belongs to α-herpesvirinae. Interestingly, we observed a similar effect of 
miR-36 mimic and inhibitor on EBV and HSV-2 infection of cells (Fig. 2F). This could be due to the fact that α, β, 
and γ-herpesviruses exhibit and share a common three-dimensional capsid structure along with the fact that there 
is quite a bit of homology in the glycoproteins being expressed on the viral envelope35.
One miRNA may regulate many genes as its targets, while one gene may also be targeted by many miRNAs36. 
Accordingly, miR-36 can possibly target several genes (Supplemental Fig. 6). Using bioinformatics tools, we iden-
tified IFITM1 to be the most promising targets to miR-36. IFITM is a member of the interferon-induced 125–133 
amino acid protein family including IFITM1, IFITM2, IFITM3, IFITM5 and IFITM10. This family of proteins is 
Figure 3. miR-36 overexpression inhibits EBV and HSV-2 infection of BJAB cells. BJAB was either 
untransfected, mock transfected, transiently transfected with miR-36 mimic (miR-mimic), co-transfected 
with miR-36 mimic and miR-36 inhibitor (miR-mimic + mir-inhib), or co-transfected with miR-36 mimic 
and nonspecific inhibitor (miR-mimic + mir-NS) prior to infecting the cells with 10 MOI of EBV or HSV-2. 
Data was plotted to represent the percentage of virus infection as determined by monitoring the change in 
RNA copy numbers of EBV-BRLF1 or HSV-2 US1 as detected in transfected cells compared to that detected in 
untransfected cells (1750 copies of EBV BRLF-1 and 2678 copies of HSV-2 US1). Bars represent average ± s.d. 
of five individual experiments. Student t test was performed to compare viral infection of untransfected cells 
versus cells transfected with miR-36 mimic, inhibitor, miR-NS, or mock transfected cells. Two-tailed P value of 
0.05 or less was considered statistically significant. ***p < 0.001; NS-not significant.
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located on chromosome 11 of the human genome and originally described as highly inducible genes by α- and 
γ-interferons (IFNs)37,38. The three members of the IFITM proteins (IFITM1, IFITM2, and IFITM3) have gained 
prominence as novel antiviral IFN-stimulated genes (ISGs)39. Hence, we set out to test the effect of transfect-
ing target cells with IFITM1-3 genes on KSHV infection of target cells. Over-expressing IFITM1 significantly 
enhanced KSHV infection of cells; IFITM3 moderately enhanced KSHV infection while IFITM2 did not alter 
the viral infection (Supplemental Fig. 7). Based on these results, we focused our further studies on IFITM1 in 
terms of miR-36 and early stages of KSHV infection. Using bioinformatic tools it was determined that the miR-36 
target IFITM1 expression. Luciferase assay demonstrated the ability of miR-36 to physically interact with IFITM1 
(Fig. 4B). miR-36 mimic specifically inhibited IFITM1 expression that could be reverted by transfecting cells 
with miR-36 inhibitor (Fig. 4B). There was an apparent inverse correlation observed between the KSHV-induced 
IFITM1 expression and miR-36 response (Fig. 4C,D). We propose the sharp decline in the expression of IFITM1 
30 min PI is because of an increase in the expression of miR-36 (Fig. 4C,D). Taken together, our study established 
a direct association between virus-induced IFITM1 and endogenous miR-36 expression in the biology of KSHV.
IFITM1 is expressed in many cell types including leukocytes and endothelial cells37,40. IFITM1 modulates cell 
functions including immunological responses, cell proliferation, cell adhesion, and germ cell maturation41. As 
other IFITM proteins, IFITM1 is significantly upregulated by interferons type I and II and is critical for anti-virus 
Figure 4. miR-36 targets IFITM1. (A) miR-36 mimic lowers KSHV-induced IFITM1 expression. Western 
blotting analysis demonstrate a decrease in IFITM1 protein levels upon over-expression of miR-36 mimic. BJAB 
and HMVEC-d cells were either untransfected, transiently transfected with miR-36 mimic, or transfected with 
control mimic (miR-NC) prior to infecting cells with 10 MOI of KSHV. Monitoring IFITM1 protein levels was 
performed 15 minutes post KSHV infection and normalized to β-actin protein levels. Data representing the 
IFITM1 protein expression levels are presented as fold increase (average ± s.d. from three experiments) in the 
boxes below the panels. The results presented are a representative data and the original full-length blots of the 
cropped images is provided in Supplemental Fig. 3. (B) miR-36 specifically binds and interact with IFITM1. 
Luciferase activity in 293 cells transfected with Dual-luciferase vector encoding Gaussia Luciferase (GLuc) 
and secreted alkaline phosphatase (SEAP) with 3′UR of IFITM placed downstream of Glu luciferase reporter 
(IFITM1 3′UTR). 293 cells were either transfected with IFITM1 3′UTR, co-transfected with IFITM1 3′UTR 
and miR-36 mimic, co-transfected with IFITM1 3′UTR and control mimic (miR-NC), or co-transfected with 
IFITM1 3′UTR, miR-36 mimic and miR-36 inhibitor. GLuc activity was monitored at 18 h, 24 h, 36 h, 84, 
and 72 h post-transfection and was normalized to SEAP. Data is plotted as GLuc/SEAP ratio where the x-axis 
indicates the transfection and time points, and y-axis indicates the relative luciferase activity. The relative 
expression of IFITM1 and miR-36 in KSHV-infected BJAB (C) and HMVEC-d (D) cells was monitored by 
qRT-PCR. The expression was measured in terms of cycle threshold value (Ct) and normalized to expression 
of β-actin and snRNA RNU6B, respectively. The x-axis denotes the time point post KSHV infection in minutes 
and y-axis denotes fold change in expression of IFITM1 and miR-36. The R2 values for the miRNA expression 
during the early course of KSHV infection is provided. Bars (B–D) represent average ± s.d. of five individual 
experiments. Student t test was performed to compare groups. Two-tailed P value of 0.05 or less was considered 
statistically significant. *p < 0.05; **p,0.01; ***p < 0.001; NS-not significant.
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response of innate immunity42. Recent reports indicate IFITM1 to play a significant role in virus entry. IFITM1 
inhibits entry of many RNA viruses including influenza A H1N1 Virus, West Nile Virus, Dengue Virus, HIV, 
and HCV42–44. The suggested mechanisms by which IFITM proteins restrict the above virus infections include 
inhibition of virus binding to corresponding cellular receptors, inhibition of endocytosis, and acting as pattern 
recognition receptors by sensing virus infection and activation of downstream cellular signaling pathways42. 
These proteins inhibit fusion of viral membranes with cellular endosomal vesicular membranes by blocking 
the creation of hemifusion, reducing membrane fluidity and curvature, and by possibly disrupting intracellular 
cholesterol homeostasis45,46. However, IFITMs can also enhance viral infection of cells: (i) both IFITM1 and 
IFITM3 modestly enhanced human papillomavirus 16 (HPV-16) infection of a variety of cells47; and (ii) Zhao 
et al. have shown type I IFN-α, IFN-γ, and type II IFN-λ to significantly promote infection of human coronavi-
rus, HCoV-OC43 by the induction of IFITM proteins. The authors reported that the over-expression of IFITM3 
significantly increased susceptibility of Huh7.5 cells to HCoV-OC43 infection48. In general, the IFITM family of 
proteins affects virus entry of cells. Over-expression of IFITM1 significantly enhanced KSHV infection of target 
cells (Fig. 5C,D) while silencing expression of IFITM1 had the opposite effect (Fig. 6). More interestingly, we 
observed identical effects of IFITM1 in enhancing EBV and HSV-2 infection of cells (Fig. 6C).
IFNs are generally considered to be antiviral cytokines that inhibit virus infection of cells by stimulating 
ISGs49. In fact, we observed a significant increase in the expression of IFN-α and -γ during the early stages of 
KSHV infection of BJAB and HMVEC-d cells (Supplemental Fig. 8). If that is the case, how can IFITM1 enhance 
infection of not just KSHV; but also of EBV and HSV-2? Such a scenario can be possible only if the virus infection 
is not altered by IFNs and associated proteins48. Interestingly enough, herpesviruses as a group (including KSHV) 
is considered to be relatively insensitive to the antiviral effects of IFNs in a variety of different cell systems50,51. In a 
way, our results demonstrate for the first time that herpesviruses, KSHV, EBV, and HSV-2, not only hijack IFITM1 
to their benefit in facilitating virus entry into cells but also evade the IFN-induced antiviral effects.
This study provides a new insight to virus infection. KSHV (including EBV and HSV-2) interactions with 
target cells induce IFITM1 within minutes, which facilitate virus entry into cells. KSHV-induced IFITM1 is part 
Figure 5. IFITM1 overexpression enhances KSHV infection of cells. (A) KSHV infection of cells induce 
IFITM1 expression. Western blotting analysis demonstrate KSHV infection of target cells to increase IFITM1 
protein levels. Expression of IFITM1 levels was normalized to β-actin protein levels. Data representing the 
IFITM1 protein expression levels are presented as fold increase (average ± s.d. from three experiments) in 
the boxes below the panels. The results presented are a representative data and the original full-length blots of 
the cropped images is provided in Supplemental Fig. 4. (B) Flow cytometry data confirming the expression of 
IFITM1 protein in transfected cells. BJAB and HMVEC-d cells transiently transfected with pQCXIP/IFITM1 
vector were analyzed for the expression of IFITM1 protein. This was performed by staining untransfected 
cells (red line) and transfected cells (green line) with rabbit polyclonal anti-IFITM1 antibodies followed by 
incubation with goat anti-rabbit FITC, before examining by FACS. As a control for the antibodies, transfected 
cells stained only with polyclonal anti-IFITM1 antibodies (purple dark line) were used. (C,D) IFITM1 enhances 
KSHV infection of cells. (C) BJAB and (D) HMVEC-d cells were untransfected, mock transfected, transiently 
transfected with pQCXIP/IFITM1, pQCXIP, co-transfected with pQCXIP/IFITM1 and miR-36 mimic, or 
co-transfected with pQCXIP/IFITM1 and control mimic (miR-NC) prior to infecting with 10 MOI of KSHV, 
EBV or HSV-2. Data was plotted to represent the percentage of virus infection as determined by monitoring the 
change in RNA copy numbers of KSHV-ORF50, EBV-BRLF1 or HSV-2 US1, respectively. Bars (C,D) represent 
average ± s.d. of five individual experiments. Student t test was performed to compare the effects of IFITM1 and 
miR-36 mimic on virus infection of cells compared to appropriate control groups. Two-tailed P value of 0.05 or 
less was considered statistically significant. **p,0.01; ***p < 0.001; NS-not significant.
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of the innate immune activation system that occurs in an antigen-independent fashion52 and relies on the ability 
of the host to recognize virus via specific pattern recognition receptors53. To counter the effects of KSHV-induced 
IFITM1, infected cells respond within a short period of time by inducing expression of miR-36. Cellular miR-36 
in turn inhibits expression of IFITM1 and thus limit virus infection of cells. Perhaps, this could be a mecha-
nism of superinfection resistance (SIR)54 developed by cells towards KSHV and other related viral pathogens. 
IFITM1 suppression by miR-36 may have direct and indirect effects of KSHV pathobiology: (i) directly limit 
KSHV infection of cells; (ii) block cell proliferation/division55 and thereby promote KSHV latency56; and (iii) 
reduce virus-induced inflammation. Such effects of IFITM1 on the biology of KSHV will be better understood by 
employing the three-dimensional (3-D) cell culture models as they mimic certain aspects of the tissue environ-
ment57,58. For all this time, studies on virus entry have always focused primarily on the roles of virus encoded gly-
coproteins and their cognate host cell receptors. To our knowledge, this is the first report of a miRNA influencing 
KSHV infection of cells and this, we hope, will open doors to a further understanding of virus entry; after all, it is 
the miRNAs that regulate the gene function.
Of late, miRNA-based therapeutics have been used to effectively treat autoimmune diseases59, and cancers 
including prostate cancer, and leukemia60 in animal models. The fact that miRNAs can influence virus entry is 
fascinating as miRNA-based therapeutics like the use of miR-mimics can effectively be used to treat virus entry 
including pathogenesis. There are several questions that need to be answered and they are as follows: (i) How does 
IFITM1 enhance KSHV infection of cells? Does it physically bind KSHV envelope-associated protein and facili-
tate endocytosis? (ii) What is the role of host cell receptors in the IFITM1-facilitated virus entry? (iii) What is the 
dynamics between the expression pattern of IFITM1 and 3 in regulating KSHV infection of cells? And (iv) Can 
induction of miR-36 by KSHV infection prevent infected cells from being superinfected with KSHV and other 
related herpesviruses, in vivo? Current studies in our lab are dedicated to answer these questions.
Materials and Methods
Cells. Human Burkitt lymphoma B cell line (BJAB), human foreskin fibroblasts (HFFs; Clonetics,Walkersville, 
MD), HEK-293 (293), and dermal microvascular endothelial cells (HMVEC-ds; CC-2543; Clonetics) were used 
in this study. BJAB cells were propagated in phenol red–free RPMI medium (Invitrogen, Carlsbad, CA) while HFF 
and 293 cells were cultured in Dulbecco modified Eagle medium (DMEM) containing 10% charcoal-stripped 
Figure 6. Knock-down of IFITM1 by siRNA decreases KSHV, EBV and HSV-2 infection of cells. (A) 
Northern blotting to monitor the effect of transfecting cells with siRNA specific to IFITM1. Target cells were 
untransfected or transfected either with ds siRNA or (NS)siRNA controls. After 0, 12, 24, and 48 hours after 
transfection, total RNAwas isolated from the cells and subjected to Northern blotting as per standard protocols 
to monitor IFITM1and β-actin mRNA. Data representing the IFITM1 mRNA expression levels are presented as 
fold increase (average ± s.d. from three experiments) in the boxes below the panels. The results presented are a 
representative data and the original full-length blots of the cropped images is provided in Supplemental Fig. 5. 
(B) BJAB and HMVEC-d cells were un-transfected, transfected with IFITM1-specific siRNA, or NS- siRNA 
prior to infecting cells with 10 MOI of KSHV. IFITM1 mRNA levels was monitored at 15 min PI by Northern 
blotting and normalized to β-actin levels. (C) KSHV, EBV, and HSV-2 infection significantly lowered in cells 
silenced for IFITM1 expression. BJAB and HMVEC-d were either un-transfected, transfected with IFITM1-
specific siRNA, or transfected with (NS) siRNA before infecting with KSHV, EBV or HSV-2. Data was plotted 
to represent the percentage of virus infection as determined by monitoring the change in RNA copy numbers 
of KSHV-ORF50, EBV-BRLF1, or HSV-2 US1. Bars represent average ± s.d. of five individual experiments. 
Student t test was performed to compare groups. Two-tailed P value of 0.05 or less was considered statistically 
significant. ***p < 0.001.
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fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA), L-glutamine, and antibiotics61. HMVEC-d cells 
were propagated in EGM MV-microvascular endothelial cell medium (Clonetics) as per standard protocols. The 
passage numbers for HFFs and HMVEC-ds used in this study ranged between 6–10, and 5–9, respectively. All the 
cells used in this study were negative for mycoplasma as tested by Mycoplasma PCR ELISA, Roche Life Science. 
For culture conditions, refer to supplemental data.
Virus. The viruses used in this study were wild-type KSHV26, herpes simplexvirus-2 (HSV-2)62, and 
Epstein-Barr virus (EBV)63. We generated ultraviolet (UV) inactivated KSHV (UV.KSHV) as per early studies20.
Cytotoxicity assay. The LDH assay was performed using the CytoTox 96 non-radioactive kit (Promega) as per 
earlier studies26. Target cells were treated with different concentrations of miR-36 mimic and inhibitor at 37 °C in a 
V-bottom 96-well plate. After a 24 h incubation, the cells were analyzed for the expression of LDH, as an indicator of 
cell death. The LDH assay was performed using the CytoTox 96 non-radioactive kit (Promega) as per earlier studies26. 
G418 (Sigma-Aldridge, St. Louis, MO) and cytochalasin D (Sigma-Aldridge) were used as known cell death inducers.
Virus infection of cells, RNA extraction, and monitoring virus infection. BJAB, HFF, and 
HMVEC-d cells were infected with 10 multiplicity of infection (MOI)29 of KSHV, EBV, and HSV-2. The cells 
were left uninfected or infected for 5, 10, 15, and 30 min prior to washing the cells twice in PBS and processed 
appropriately for RNA extraction. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA). The RNA 
concentration was measured with a NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA), and then verified for quality using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 
Only the RNA samples with 260/280 ratios of 1.8 to 2.0 were used in the study.
Extracted RNA was used to synthesize cDNA and the expression of ORF50 was monitored by qRT-PCR using 
specific primers as per earlier studies26 Expression of ORF50 was used as a scale to measure KSHV infection of 
cells. As reported earlier29, the lowest limit of detection in the standard samples was 6–60 copies for the ORF50 
gene. The results from the use of ORF50 primers were consistently confirmed by monitoring the expression of 
another viral immediate early (IE) gene, vGPCR (data not shown). EBV and HSV-2 infection was monitored 
using specific primers to BRLF1 (homolog of KSHV ORF50)64 and HSV-2 IE gene, US165.
Transfections of cDNA and miRNA. Target cells were transiently transfected with plasmid DNA using 
FuGene HD (Promega, Madison, WI) as per manufacturer’s recommendations. The plasmid, pQCXIP encod-
ing IFITM1, used in this study was kindly gifted to us by Dr. Michael Farzan (The Scripps Research Institute, 
Jupiter, USA). FuGene HD/DNA ratios of 3:1 for adherent cell lines and 6:1 for suspension cell lines were used. 
Transfection of target cells with different concentrations of miR-36 mimic, or scramble control (miR-NC); 
miRNA inhibitor to miR-36 and non-specific (NS) inhibitor (Sigma-Aldridge) was achieved using FuGene HD 
reagent as per standard laboratory procedures. These were transient transfections and experiments using these 
cells were conducted 48 h post transfection.
Binding assay. The effect of miR-mimic and inhibitor on KSHV binding to target cells was assessed by PCR 
detecting the cell-bound KSHV DNA. Briefly, untransfected cells or cells transfected with miR-mimic or inhibi-
tor were infected with 10 MOI of KSHV at +4 °C. After 60 min of incubation with virus, cells were washed three 
times with PBS to remove the unbound virus. Cells were pelleted, and total DNA including those representing the 
cell bound KSHV was isolated using DNeasy kit (Qiagen, Valencia, CA) and subjected to qPCR analysis monitor-
ing ORF50 according to recently published work29. Incubating KSHV with 100 µg/ml of heparin and chondroitin 
sulfate A (CSA; Sigma-Aldridge) for 1 h at 37 °C were used as known positive and negative controls.
Flow cytometry. Flow cytometry was used to monitor expression of IFITM1 in the cells as per earlier proto-
cols29. Briefly, target cells were fixed in 10 ml of ice-cold acetone for 20 min, washed thrice in PBS prior to incubating 
cells in 25 µg/ml of rabbit polyclonal antibody to IFITM1 (EMD Millipore, Billerica, MA) for 60 min at 4 °C. The 
cells were washed thrice in PBS and further incubated with FITC conjugated appropriate secondary IgG at 4 °C for 
30 min, washed and analyzed in a FACScan flow cytometer (Becton Dickinson) with appropriate gating parameters.
Western blotting. All the buffers used in this project were made with water that was endotoxin and 
pyrogen free. Western blotting was conducted as per earlier studies29 using the following primary antibod-
ies: rabbit anti-IFITM1 polyclonal antibody (EMD Millipore) and mouse anti-actin antibodies (Clone AC-74; 
Sigma-Aldridge).
Real-time qRT-PCR analysis of the expression of miRNAs and IFNs. The quality of RNA was 
tested using a spectrophotometer. Only the RNA samples with 260/280 ratios of 1.8 to 2.0 were used in the study. 
Approximately 500 ng of RNA was reverse transcribed in a 25 µl reaction volume using the All-in-oneTM miRNA 
qRT-PCR detection kit (GeneCopoeia, Rockville, MD). Briefly, the cDNA was synthesized in a 25 μl reaction mix 
containing 5 μl of 5x reaction buffer, 2.5 U/μl Poly A Polymerase, 10 ng/μl MS2 RNA, and 1 µl RTase Mix. The reac-
tion was performed at 37 °C for 60 min and terminated at 85 °C for 5 min. cDNA that was produced in the RT 
reaction was diluted ten-fold and was used as the template for the PCR reaction in an Applied Biosystems ViiA 
7 Real-Time PCR System (Life Technologies, USA). In this system, MS2 RNA was used as an external reference 
for the quality of the extracted miRNAs, and RNU6B, RNU44, RNU48, and RNU49 were used for normalization. 
The expression levels of miRNAs were measured employing qRT-PCR with the SYBR green detection and specific 
forward primer for the mature miRNA sequence and the universal adaptor reverse primer (GeneCopoeia, USA). 
Expression of IFN-α, -β, and -γ by qRT-PCR was conducted as per earlier protocols26 using appropriate primers66–68.
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Dual-luciferase reporter assay. Luciferase reporter plasmids with wild-type IFITM1 3′-UTR were pur-
chased from GeneCopoeia (Rockville, MD). 293 cells were plated onto 6-well plates. At 24 h post-plating, 293 cells 
were co-transfected with IFITM1 3′-UTR luciferase reporter plasmid and miR-36 mimic or miR-NCNA scramble 
control (miR-NC) using FuGene HD (Promega). At 12, 24, 48 h post transfection, supernatants were collected 
from each treatment and the luciferase activity measured using the Secrete-Pair Dual Luminescence Assay Kit 
(GeneCopoeia) as per the manufacturers’ recommendations.
Northern blotting. Northern blotting to monitor IFITM1 and β-actin expression was performed using a 
DIG Luminescent Detection Kit (Roche, Indianapolis, IN) as per the manufacturer’s recommendations26.
Silencing IFITM1 using siRNA. Expression of IFITM1 was inhibited by the transfection of double-stranded 
(ds) RNA oligos as per standard protocols26. IFITM1 siRNA was purchased from Dharmacon RNA Technologies 
(Lafayette, CO). Briefly, 1 × 106 cells were washed twice in RPMI and incubated in phenol red–free RPMI sup-
plemented with 5% FBS at 37 °C. After 24 hours incubation (considered as 0 h for experiments in Fig. 6A), the 
target cells were transfected with either ds short interfering RNAs (siRNAs) or the nonspecific (NS) controls using 
Fugene HD as per manufacturer’s recommendations (Promega). At 0, 12, 24, and 48 hours after transfection, 
total RNA was isolated from the cells and subjected to Northern blotting to monitor the expression of IFITM1 
and β-actin mRNA as per the protocol mentioned in the “Materials and methods” section describing Northern 
blotting. In another set of experiments, untransfected cells and cells transfected with siRNA or (NS) siRNA for 
12 h were infected with 10 MOI of KSHV. At the end of 30 min PI, KSHV infection was assessed by monitoring 
ORF50 expression by qRT-PCR.
Data Availability Statement. All data generated or analyzed during this study are included in this pub-
lished article (and its Supplementary Information files).
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